Log In Sign up
The largest database of trusted experimental protocols

B6.129s c batf3tm1kmm j mice

Manufactured by Jackson ImmunoResearch
Visit Supplier
Sourced in United States

B6.129S(C)-Batf3tm1Kmm/J mice are a genetically-modified mouse strain with a targeted mutation in the Batf3 gene. The Batf3 gene is involved in the development and function of a specific type of immune cell called a dendritic cell. These mice can be used in research to study the role of dendritic cells in various biological processes.

Automatically generated - may contain errors

Lab products found in correlation

Female c57bl 6 mice, by Charles River Laboratories (1 mentions) Balb c nude, by Orient Bio (1 mentions) C57bl 6 tg tcratcrb 1100mjb j, by Jackson ImmunoResearch (1 mentions) C57bl 6 mice, by Orient Bio (1 mentions) Balb c, by Orient Bio (1 mentions)

4 protocols using b6.129s c batf3tm1kmm j mice

1

Establishment and Characterization of Murine Ovarian Cancer Models

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Female C57BL/6 mice were obtained from Charles River Laboratories (Wilmington, MA, USA). B6.129S(C)-Batf3tm1Kmm/J mice were purchased from The Jackson Laboratory (Sacramento, CA, USA). Experimental procedures were performed in compliance with protocols approved by the Institutional Animal Care and Use Committee of the Roswell Park Comprehensive Cancer Center (RPCCC, Buffalo, NY, USA). The parental ID8 mouse ovarian epithelial cell line, derived from spontaneous malignant transformation of C57BL/6 MOSE cells,60 (link) and its metastatic variant ID8-T were established in our laboratory at the RPCCC.6 (link) Human HuTK− 143 fibroblasts, human cervical carcinoma HeLa cells, and the African green monkey cell line CV-1 were obtained from the American Type Culture Collection (Manassas, VA, USA).
Mistarz A., Komorowski M.P., Graczyk M.A., Gil M., Jiang A., Opyrchal M., Rokita H., Odunsi K.O, & Kozbor D. (2019). Recruitment of Intratumoral CD103+ Dendritic Cells by a CXCR4 Antagonist-Armed Virotherapy Enhances Antitumor Immunity. Molecular Therapy Oncolytics, 14, 233-245.
+ Open protocol
+ Expand
2

Mouse Maintenance for Immunological Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols
BALB/c, BALB/c nude, and C57BL/6 mice (age, 8 weeks) were purchased from Orient Bio. C57BL/6-Tg(TcraTcrb)1100Mjb/J and B6.129S(C)-Batf3tm1Kmm/J mice were purchased from The Jackson Laboratory. All mice were maintained and raised in a specific pathogen–free animal room at the Korea Institute of Science and Technology (KIST). All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) of KIST.
Kim G.B., Nam G.H., Hong Y., Woo J., Cho Y., Kwon I.C., Yang Y, & Kim I.S. (2020). Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity. Science Advances, 6(27), eaaz2083.
+ Open protocol
+ Expand
3

Syngeneic Melanoma and Colon Carcinoma Models in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
For injections of Braf and Braf/Pten Melanoma 6-12-week-old male/female immune-competent B6(Cg)-Tyrc-2J/J or male/female immune-compromised 6-24-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ (NSG) mice were used. As recipients for ACT 6-12-week-old, male/female B6(Cg)-Rag2tm1.1Cgn/J Ly5.2 mice [Rag2-/-] were used. CT26 colon carcinoma cells were injected into 6-12-week-old male/female BALB/cJ. These mice were received from the in-house breeding facility and bred and housed under standard pathogen-free conditions at a housing temperature of 22 (±1) degrees, 55 (±5) % humidity and a photoperiod of 14h light, 10h dark. T cell isolation was performed from 8-20-week-old male/female OT-1 Rag2-/- mice, or 8-20-week-old male/female OT-1 Luc Thy1.1 mice58 (link). B6.129S(C)-Batf3tm1Kmm/J mice were purchased from Jackson laboratories and used for injection of the Braf melanoma model at an age of 6-12 weeks.
Haas L., Elewaut A., Gerard C.L., Umkehrer C., Leiendecker L., Pedersen M., Krecioch I., Hoffmann D., Novatchkova M., Kuttke M., Neumann T., de Silva I.P., Witthock H., Cuendet M.A., Carotta S., Harrington K.J., Zuber J., Scolyer R.A., Long G.V., Wilmott J.S., Michielin O., Vanharanta S., Wiesner T, & Obenauf A.C. (2021). Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma. Nature cancer, 2(7), 693-708.
+ Open protocol
+ Expand
4

Syngeneic Melanoma and Colon Carcinoma Models in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
For injections of Braf and Braf/Pten Melanoma 6-12-week-old male/female immune-competent B6(Cg)-Tyrc-2J/J or male/female immune-compromised 6-24-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ (NSG) mice were used. As recipients for ACT 6-12-week-old, male/female B6(Cg)-Rag2tm1.1Cgn/J Ly5.2 mice [Rag2-/-] were used. CT26 colon carcinoma cells were injected into 6-12-week-old male/female BALB/cJ. These mice were received from the in-house breeding facility and bred and housed under standard pathogen-free conditions at a housing temperature of 22 (±1) degrees, 55 (±5) % humidity and a photoperiod of 14h light, 10h dark. T cell isolation was performed from 8-20-week-old male/female OT-1 Rag2-/- mice, or 8-20-week-old male/female OT-1 Luc Thy1.1 mice58 (link). B6.129S(C)-Batf3tm1Kmm/J mice were purchased from Jackson laboratories and used for injection of the Braf melanoma model at an age of 6-12 weeks.
Haas L., Elewaut A., Gerard C.L., Umkehrer C., Leiendecker L., Pedersen M., Krecioch I., Hoffmann D., Novatchkova M., Kuttke M., Neumann T., de Silva I.P., Witthock H., Cuendet M.A., Carotta S., Harrington K.J., Zuber J., Scolyer R.A., Long G.V., Wilmott J.S., Michielin O., Vanharanta S., Wiesner T, & Obenauf A.C. (2021). Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumour microenvironment and cross-resistance to immunotherapy in melanoma. Nature cancer, 2(7), 693-708.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!